Back to Search
AHMED AL-KATIB, MD
MD
Psychiatry Physician
NPI: 1235651944Individual
Specialties, Licenses & Credentials
Psychiatry PhysicianPrimary
Psychiatry & Neurology — Psychiatry
Code: 2084P0800X
310649(NY)
Research & Publications (20)
Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
PMID 19509168·Clin Cancer Res·2009
4-observational
SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status.
PMID 19220884·J Hematol Oncol·2009
7-preclinical
Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.
PMID 18769131·Cancer Biol Ther·2008
7-preclinical
Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.
PMID 18275607·Mol Cancer·2008
7-preclinical
Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes.
PMID 17654686·Am J Hematol·2007
8-other
Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
PMID 17404107·Clin Cancer Res·2007
7-preclinical
Variant lymphoproliferative disorder of granular lymphocytes (LDGL) following Hodgkin lymphoma.
PMID 15929104·Am J Hematol·2005
5-case
Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells.
PMID 15777935·J Immunol Methods·2005
7-preclinical
Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
PMID 15657349·Mol Cancer Ther·2005
7-preclinical
Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma.
PMID 15370253·Leuk Lymphoma·2004
3-trial
Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.
PMID 15202025·Int J Mol Med·2004
8-other
Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
PMID 14707277·Mol Cancer Ther·2003
7-preclinical
Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model.
PMID 14654565·Clin Cancer Res·2003
7-preclinical
XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways.
PMID 14612935·Int J Oncol·2003
8-other
The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.
PMID 12720160·Semin Oncol·2003
7-preclinical
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
PMID 12720118·Semin Oncol·2003
6-review
2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
PMID 12516965·Mol Cancer Ther·2002
8-other
2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.
PMID 12516964·Mol Cancer Ther·2002
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 134 BROADWAY FL 4
BROOKLYN, NY 11249 - Phone
- (646) 427-3434
Quick Facts
- NPI
- 1235651944
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile